Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

https://www.jthjournal.org/article/S1538-7836(25)00109-6/fulltext
Antithrombotic agents, like aspirin and anticoagulants, are essential for treating many cardiovascular conditions. However, a common side effect is bleeding, with extracranial bleeding—bleeding outside the brain and spinal cord—being quite prevalent. This study, a secondary analysis of the Aspirin in Reducing Events in the Elderly, or ASPREE trial, aimed to explore how clinically significant extracranial bleeding affects the development of functional disability in otherwise healthy older adults.

What did the researchers find?

Summary of Findings:

  • Incidence of Bleeding: Out of nearly 19,000 participants, about 2.9%, or 547 individuals, experienced clinically significant extracranial bleeding.
  • Functional Independence Impact: Those who experienced such bleeding had a more than two-fold increase in the risk of developing dependence on activities of daily living, or ADLs. Specifically, the hazard ratio for ADL dependence was 2.46, indicating a significant association.
  • Types of Bleeding: Both gastrointestinal (GI) bleeding and other non-GI extracranial bleeding showed similar risks, with hazard ratios of 2.29 and 2.68 respectively. Importantly, these associations held true whether participants were on aspirin or a placebo.

Strengths of the Study:

  1. Large Sample Size: With nearly 19,000 participants, the study provides robust data.
  2. Rigorous Data Collection: Bleeding events were meticulously documented and adjudicated by medical professionals.
  3. Comprehensive Analysis: The detailed follow-up and frequent assessments allowed for thorough monitoring of participants' health outcomes over several years.

Weaknesses of the Study:

  1. Granular Data Absence: Specific details about hospitalization, such as length of stay or the number of transfusions, were not available.
  2. Data Collection Frequency: Bleeding events were assessed continuously, whereas ADL dependence was assessed biannually. This discrepancy could lead to challenges in pinpointing the exact onset of functional dependence relative to bleeding events.

Jaksot(385)

126. Corona Virus, COVID19, Pregnancy, Pre-symptomatic Spread

126. Corona Virus, COVID19, Pregnancy, Pre-symptomatic Spread

More cover 19 information based on antibody testing, pregnancy and pre-symptomatic spreadhttps://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1.full.pdfhttps://www.nejm.org/doi/full/10.1056/NEJ...

20 Huhti 202025min

125. Remdesivir, Covid19, Corona Virus, NEJM Treatment

125. Remdesivir, Covid19, Corona Virus, NEJM Treatment

Remdesivir for compassionate use?? Recently published in the New England Journal of Medicine- Is this the COVID19 treatment we have all be hoping for.https://www.nejm.org/doi/full/10.1056/NEJMoa200701...

14 Huhti 202023min

124. COVID19, Corona Virus and TREATMENT (that works)

124. COVID19, Corona Virus and TREATMENT (that works)

Treatment that works-- MASK!https://annals.org/aim/fullarticle/2764367/effectiveness-surgical-cotton-masks-blocking-sars-cov-2-controlled-comparisonHigh Velocity Nasal Insufflation (HVNI) Therapy Appl...

10 Huhti 202016min

123. COVID19, ACE inhibitors, Corona Virus, Testing

123. COVID19, ACE inhibitors, Corona Virus, Testing

Id be happy to send you links to any of the articles talked about in this podcast but I cover the new test on the corona virus that claims to be great but the devil in the details as well as talk abou...

9 Huhti 202019min

122. Hydroxychloroquine, COVID19, Coronavirus, research

122. Hydroxychloroquine, COVID19, Coronavirus, research

https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v1.full.pdf https://www.sciencedirect.com/science/article/pii/S0399077X20300858 https://first10em.com/chloroquine-for-covid-no-good-evidence-...

3 Huhti 202016min

121. COVID19, Hydroxychloroquine, Azithromycin, Coronavirus, TREATMENT

121. COVID19, Hydroxychloroquine, Azithromycin, Coronavirus, TREATMENT

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FRhttps://www.sciencedirect.com/science/article/pii/S0924857920300996?via%3Dihub

26 Maalis 202021min

120. Question Everything- Stop Hear-Say medicine

120. Question Everything- Stop Hear-Say medicine

Question Everything-- EBM not hear-say medicine

24 Maalis 202024min

119. Aimovig or Erenumab Prescription Description

119. Aimovig or Erenumab Prescription Description

A listener wrote in with a question about a drug, this is my response. Let me know your thoughts? Would you prescribe this drug? Andrewbuelt@gmail.comhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1705848

13 Maalis 202024min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
psykopodiaa-podcast
tiedenaiset-podcast
voi-hyvin-meditaatiot-2
vakeva-elama-viisaampi-mieli-vahvempi-keho
rss-pitaisko-erota
rss-pt-paahtio
rss-narsisti
puhu-muru
rss-kuumilla-aalloilla
meditaatiot-suomeksi
selviytyjat-tarinoita-elamasta
terapiassa
rss-nautinto
junnut-pelissa
rss-uplevel-by-sonja-hannus
rss-addiktit
rss-mighty-finland-podcast
rss-en-saa-unta
rss-fitissa-podcast